Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Researchers Grow Expensive Cancer Drug In Chicken Eggs

By Meagan Parrish | October 10, 2017

A group of Japanese scientists are hoping to help drive down the cost of an expensive cancer drug by growing an active ingredient in chicken eggs.

According to a report in Newsweek, the researchers have edited the genomes of hens so that they will lay eggs containing interferon, a protein that helps stop cancer cells from growing and multiplying.

Using current production methods, a few micrograms of interferon costs $250 and $900 to make. The high price tag can make it cost prohibitive for patients, who often need to inject it three times a week. By instead using genome-editing technology to grow the drug in chickens, who lay an egg every day or two, the researchers hope they can sell interferon at about half of what it costs now, and eventually lower it to less than 10 percent of the current price.

“This is a result that we hope leads to the development of cheap drugs,” professor Hironobu Hojo of Osaka University, where the research was conducted, told The Japan News. “In the future, it will be necessary to closely examine the characteristics of the agents contained in the eggs and determine their safety as pharmaceutical products.”

Japan News reports that a joint research company hopes to begin selling the interferon, which is also used to treat hepatitis and multiple sclerosis, as early as next year.


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50